GlassScriptPhysician profile
Ashli Mullins
NPI 1427525377
$2,460.57
in general payments reported to CMS, 2019-2025
28 companies · $686 in 2025
The $686 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $263 · 2023: $674 · 2024: $637 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882 · Consulting Fee: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.49 |
| Consulting Fee | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $378.57 | 2021-2025 | Invega Sustenna, Spravato, Invega |
| Abbvie INC. | $256.10 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $231.83 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $213.79 | 2021-2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $199.65 | 2022-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $182.90 | 2021-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $144.58 | 2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $129.47 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $127.31 | 2023-2025 | Auvelity |
| Janssen Scientific Affairs, LLC | $115.00 | 2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $74.95 | 2024-2025 | Uzedy |
| Corcept Therapeutics | $52.68 | 2023-2024 | Korlym |
| Sunovion Pharmaceuticals INC. | $38.13 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.75 | 2025 | Cobenfy |
| Tris Pharma INC | $32.29 | 2024 | Dyanavel Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $31.49 | 2023 | Qelbree |
| Neurocrine Biosciences, INC. | $30.33 | 2022-2025 | |
| Corium, LLC | $22.08 | 2023 | Azstarys |
| Indivior INC. | $22.00 | 2024 | Perseris |
| Novartis Pharmaceuticals Corporation | $20.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.47 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $16.72 | 2021 | |
| Ardelyx, INC. | $16.25 | 2025 | Ibsrela |
| Ironshore Pharmaceuticals INC. | $15.32 | 2023 | Jornay Pm |
| Boston Scientific Corporation | $15.28 | 2024 | Bodyguardian |
| Genentech USA, INC. | $15.18 | 2021 | |
| Verona Pharma, INC. | $14.78 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $8.87 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashli Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.